Clostridium diffi cile is the most burdensome gastrointestinal infection and one of the main infectious causes of morbidity and mortality in industrialised countries.
1 Prevention of C diffi cile infection relies on methods to reduce transmission of the pathogen, through eff ective hand hygiene, barrier precautions, isolation of patients, and environmental cleaning. Perhaps even more important are attempts to reduce host susceptibility to infection by decreasing unneces sary antibiotic use. 2 Antibiotic use disrupts and depletes the normal gastrointestinal fl ora, allowing C diffi cile to thrive and generate clinical disease. 3 When antibiotic treatment is unavoidable, reinforcement of the colonic fl ora might be another means to decrease susceptibility of patients to C diffi cile. Defi nitive restoration of the colonic ecosystem through stool transfer has unequivocal benefi t in treatment of established C diffi cile infections and prevention of recurrences. 4 A more palatable, or at least less pungent, approach to boost colonic defences is the use of non-pathogenic microbial supplements-known as pro biotics. Probiotics have been widely marketed in commercial preparations, and widely studied as a means to prevent C diffi cile. Two recent meta-analyses have sum marised the results of previous trials, detecting large reductions in the risk of antibiotic-associated diar rhoea (AAD) in general (relative risk [RR] 0·58, 95% CI 0·50-0·68) 5 and C diffi cile infections in particular (0·34, 0·24-0·49). 6 These impressive eff ect sizes are motivating many health-care institutions to consider routine probiotic coadministration with antibiotic treatments.
However, in The Lancet, Stephen Allen and colleagues 7 question the usefulness of routine probiotics. Their PLACIDE trial, done at fi ve centres in England and Wales, is the largest trial to be reported in this discipline (n=2941). The study is rigorous, with central A probiotic trial: tipping the balance of evidence?
health care are to be universal human rights, then we need to understand how unfair the distribution is of both health status and health services. Second, examination of the equitable distribution of key indicators of social determinants of health. I propose four: early child development at age 5 years; the proportion of young people not in employment, education, or training; an adult poverty measure; and a measure of social isolation or poverty or both in people older than working age. Problems of international comparability will arise, but these are soluble, as shown by the Human Development Reports or regular World Bank reports.
Personally, I would not stop there. I would want the monitoring framework to include inequities in power, money, and resources-the structural drivers of health inequity highlighted by the Commission on Social Determinants of Health. For example, in London, UK the eff ects of the economic downturn on health equity will be monitored by indicators of employment, economic security, housing, and migration. Although these are all important, the four areas I have proposed are eminently doable, and should be done, by any country that is serious not just about ensuring universal coverage of health services but equity in health of its population. randomisation, use of placebo control, careful allocation concealment, and thorough follow-up for evidence of AAD or C diffi cile diarrhoea (CDD). A 21-day treatment with a combined preparation of lactobacilli and bifi dobacteria neither reduced the risk of AAD (RR 1·04, 95% CI 0·84-1·28) nor that of CDD (0·71, 0·34-1·47). How do we reconcile the large negative PLACIDE trial with the large positive eff ects detected in previous meta-analyses, especially since the sample size in PLACIDE dwarfs that of any previous studies in the discipline? 6 To address this notion, I recreated the forest plot from the previous meta-analysis of the eff ect of probiotic use on the outcome of C diffi cile infection (fi gure; Review Manager, version 5.1, Cochrane Collaboration, Copenhagen, Denmark). The 95% CIs of the PLACIDE result visually overlap those of previous studies, and there is no statistical evidence of additional heterogeneity (I²=0). Importantly, addition of the PLACIDE results barely shifts the risk reduction estimate, from 0·34 (95% CI 0·24-0·49) to 0·39 (0·29-0·54). Although the sample size of PLACIDE was very large, the event rate was much lower than predicted (about 10% occurrence of ADD compared with a prediction of 20%; 1% occurrence of CDD compared with a prediction of 4%). 7 Perhaps the PLACIDE trial was negative because its 95% CIs were unable to rule out a potential 16% reduction in occurrence of AAD and a potential 66% reduction in CDD.
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Alternatively, maybe the results of this single large randomised trial should outweigh the results of any meta-analysis. 8 Most previous probiotic research has involved small, single centre studies of variable quality. Even when a meta-analysis is carefully done, it is limited by the quality of included studies, and might introduce additional bias through study selection and data pooling methods. 9 A third of meta-analyses do not accurately predict the results of subsequent large randomised controlled trials and, generally, a well done trial serves as the gold standard of evidence. 8 At the very least, the low absolute risk reductions in PLACIDE question the cost-eff ectiveness of probiotics. A cost-consequence analysis funded by a probiotic manufacturer established that the incidence of CDD must be more than 1·2% for this strategy to produce cost Age-related macular degeneration is the leading cause of blindness in developed countries. 1 Since the mid2000s, intraocular injections of agents inhibiting vascular endothelial growth factor (VEGF) have become the mainstay of treatment for neovascular (wet) age-related macular degeneration. [2] [3] [4] Emerging data from national registries show that blindness related to age-related macular degeneration started to fall when anti-VEGF treatment was introduced. 5 However, three key questions remain unanswered for physicians, their patients, and policy makers. First, what is the most cost-eff ective drug? Two anti-VEGF agents are available: ranibizumab, which was approved by the US Food and Drug Administration, and bevacizumab, which is a cancer drug widely used off label.
1 Bevacizumab costs a fraction of ranibizumab, and is the main drug used in many non-reimbursed settings, such as in US practice. 6 A report 6 suggested that US Medicare could save more than US$1 billion within 2 years if bevacizumab replaced ranibizumab. Second, how often should injections be given? Initial clinical trials 3, 4 suggested that ranibizumab should be given monthly for the best visual outcome. In clinical practice, physicians and patients would obviously prefer injections with intervals of longer than 1 month, and alternative regimens (eg, as needed) have been proposed. However, whether such alternative regimens have acceptable results is unclear. Third, does longterm treatment have safety issues? Although anti-VEGF agents are injected in small quantities into the eye, concerns about systemic safety have been raised, including possible risk of stroke. 7, 8 In The Lancet, Usha Chakravarthy and colleagues report 2-year fi ndings of the IVAN randomised controlled trial. 9 This trial, along with the US CATT trial, 10, 11 attempts to answer these questions. In IVAN, adults with untreated neovascular age-related macular degeneration were randomly assigned to receive intravitreal injections of ranibizumab or bevacizumab in continuous (monthly) or discontinuous (as needed) regimens.
12 Unfortunately, the results have not clarifi ed the situation. For best corrected distance visual acuity-the primary outcomebevacizumab was neither non-inferior nor inferior to ranibizumab (mean diff erence -1·37 letters in favour of ranibizumab, 95% CI -3·75 to 1·01; prespecifi ed noninferiority limit 3·5 letters). 9 Similarly, discontinuous treatment was neither non-inferior nor inferior to continuous treatment (-1·63 letters in favour of continuous treatment, -4·01 to 0·75). 9 Can the three questions now be answered?
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savings. 10 At my own centre, the percentage of antibiotic recipients who develop CDD is right at this boundary, and so any shift in eff ect size could tip decision preferences.
PLACIDE is a large and rigorous negative study, and we must judge whether it can tip the balance of probiotic evidence. Similarly, lactobacilli and bifi dobacteria are only two types of non-pathogenic bacteria, and we must consider whether they can really tip the balance of a diverse gut ecosystem. 
